臺灣博碩士論文加值系統

人類微小病毒B19 (Human parvovirus B19, B19)屬於微小病毒科，已知會造成許多人類疾病。B19病毒的殼體蛋白是由VP1及VP2組成，其中VP1比VP2在N端多出227個胺基酸，此段區域被命名為結構蛋白獨立區域[VP1-unique region, VP1u]。文獻已知VP1u具有sPLA2酵素活性，與病毒感染有關，並且能引起IgG抗體產生。先前研究發現B19感染會引起抗磷脂質抗體產生，並且與抗磷脂質症候群密切相關。而其中B19-VP1u病毒蛋白更被發現可誘發抗磷脂質抗體產生。為了深入瞭解VP1u蛋白作用機制，我們利用不同長度片段的B19-VP1u重組蛋白進行研究分析，結果發現VP1u區域中(1)61-227a.a.片段具有較高的sPLA2酵素活性;(2) 82-227a.a.片段與抗磷脂質抗體作用密切相關；(3)注射31-227a.a.及61-227a.a.抗體的Balb/c老鼠，會導致血小板減少和aPTT凝血時間延長;(4)注射21-227a.a.、51-227a.a.抗體的Balb/c老鼠會促進腹腔巨噬細胞遷徙能力增加；(5)注射VP1u片段抗體的Balb/c老鼠會促進CD8+/CD4+/Th17/Treg/NK/B細胞表現。綜合以上結果，我們更明確瞭解B19-VP1u在B19病毒感染與抗磷脂質抗體產生的致病機制重要角色。

Human parvovirus B19 (B19) is classified as Parvoviridae family and known causing disease in humans. The virus capsid is composed of two structural proteins, VP1 and VP2, which are identical except for 227 amino acids at the amino-terminal end of the VP1-protein, the so-called VP1-unique region (VP1u). B19-VP1u proteins have secretary phospholipase A2 (sPLA2) activity, which is essential for viral infectivity and as the region to neutralize the immune response (VP1u-IgG). Previous studies show B19-VP1u induces the production of anti-phospholipid antibody. To further understand the pathogenesis of B19- VP1u, we used different region of B19-VP1u recombinant proteins to analysis. The results indicated that (1) VP1u region of 61-227a.a. has higher sPLA2 activity; (2) 82-227a.a. region has higher association with anti-phospholipid antibody; (3) Passive immunization mice which injecting 31-227a.a. and 61-227a.a. antibodies may cause thrombocytopenia and aPTT prolong; (4) Passive immunization mice which injecting 21-227a.a and 51-227a.a antibodies may activate the macrophages migration; (5)The different VP1u region can stimulate CD8+/CD4+/Th17/Treg/NK/B cells expression. All together, we firstly demonstrated the region of B19-VP1u in B19 infection and the pathogenesis of anti-phospholipid antibodies in vivo.

中文摘要 4
Abstract 5
壹、緒論 6
一、人類微小病毒B19 6
(一)分子生物學 6
(二)臨床症狀 8
(三)臨床診斷 9
(四)預防治療 10
(五)自體免疫疾病與B19病毒 10
二、人類微小病毒結構蛋白獨立區域(VP1u) 12
三、抗磷脂質症候群 14
(一)簡介 14
(二)致病機轉 16
(三)臨床治療 18
四、B19病毒感染與抗磷脂質症候群 18
貳、研究動機 20
參、實驗材料與方法 21
肆、結果 33
伍、討論 41
陸、參考文獻 48
柒、圖表 60

1.Cotmore, S.F., M. Agbandje-McKenna, J.A. Chiorini, D.V. Mukha, D.J. Pintel, J. Qiu, M. Soderlund-Venermo, P. Tattersall, P. Tijssen, D. Gatherer, and A.J. Davison, The family Parvoviridae. Arch Virol, 2014. 159(5): p. 1239-47.
2.Cossart, Y.E., A.M. Field, B. Cant, and D. Widdows, Parvovirus-like particles in human sera. Lancet, 1975. 1(7898): p. 72-3.
3.Heegaard, E.D. and K.E. Brown, Human parvovirus B19. Clin Microbiol Rev, 2002. 15(3): p. 485-505.
4.Ozawa, K., J. Ayub, S. Kajigaya, T. Shimada, and N. Young, The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol, 1988. 62(8): p. 2884-9.
5.Moffatt, S., N. Yaegashi, K. Tada, N. Tanaka, and K. Sugamura, Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol, 1998. 72(4): p. 3018-28.
6.Fu, Y., K.K. Ishii, Y. Munakata, T. Saitoh, M. Kaku, and T. Sasaki, Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol, 2002. 76(11): p. 5395-403.
7.Dorsch, S., G. Liebisch, B. Kaufmann, P. von Landenberg, J.H. Hoffmann, W. Drobnik, and S. Modrow, The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol, 2002. 76(4): p. 2014-8.
8.Brown, K.E., S.M. Anderson, and N.S. Young, Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science, 1993. 262(5130): p. 114-7.
9.Weigel-Kelley, K.A., M.C. Yoder, and A. Srivastava, Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood, 2003. 102(12): p. 3927-33.
10.Munakata, Y., T. Saito-Ito, K. Kumura-Ishii, J. Huang, T. Kodera, T. Ishii, Y. Hirabayashi, Y. Koyanagi, and T. Sasaki, Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood, 2005. 106(10): p. 3449-56.
11.Chisaka, H., E. Morita, N. Yaegashi, and K. Sugamura, Parvovirus B19 and the pathogenesis of anaemia. Rev Med Virol, 2003. 13(6): p. 347-59.
12.Wong, S., N.S. Young, and K.E. Brown, Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia. J Infect Dis, 2003. 187(10): p. 1581-6.
13.Pankuweit, S., V. Ruppert, H. Eckhardt, D. Strache, and B. Maisch, Pathophysiology and aetiological diagnosis of inflammatory myocardial diseases with a special focus on parvovirus B19. J Vet Med B Infect Dis Vet Public Health, 2005. 52(7-8): p. 344-7.
14.Rosenfeld, S.J., K. Yoshimoto, S. Kajigaya, S. Anderson, N.S. Young, A. Field, P. Warrener, G. Bansal, and M.S. Collett, Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest, 1992. 89(6): p. 2023-9.
15.Mani, B., C. Baltzer, N. Valle, J.M. Almendral, C. Kempf, and C. Ros, Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1), N-VP2 cleavage, and uncoating of the full-length genome. J Virol, 2006. 80(2): p. 1015-24.
16.Lee, C.A., Transfusion-transmitted disease. Baillieres Clin Haematol, 1996. 9(2): p. 369-94.
17.Parsyan, A. and D. Candotti, Human erythrovirus B19 and blood transfusion - an update. Transfus Med, 2007. 17(4): p. 263-78.
18.Kinney, J.S., L.J. Anderson, J. Farrar, R.A. Strikas, M.L. Kumar, R.M. Kliegman, J.L. Sever, E.S. Hurwitz, and R.K. Sikes, Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis, 1988. 157(4): p. 663-7.
19.Cohen, B.J. and M.M. Buckley, The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol, 1988. 25(2): p. 151-3.
20.Woolf, A.D., G.V. Campion, A. Chishick, S. Wise, B.J. Cohen, P.T. Klouda, O. Caul, and P.A. Dieppe, Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med, 1989. 149(5): p. 1153-6.
21.Naides, S.J., Infection with Parvovirus B19. Curr Infect Dis Rep, 1999. 1(3): p. 273-278.
22.Leung, W.C., Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG, 2000. 107(10): p. 1324.
23.Katz, V.L., M.C. McCoy, J.A. Kuller, and W.F. Hansen, An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Am J Perinatol, 1996. 13(1): p. 43-5.
24.Murray, J.C., P.K. Kelley, W.R. Hogrefe, and K.L. McClain, Childhood idiopathic thrombocytopenic purpura: association with human parvovirus B19 infection. Am J Pediatr Hematol Oncol, 1994. 16(4): p. 314-9.
25.Schowengerdt, K.O., J. Ni, S.W. Denfield, R.J. Gajarski, N.E. Bowles, G. Rosenthal, D.L. Kearney, J.K. Price, B.B. Rogers, G.M. Schauer, R.E. Chinnock, and J.A. Towbin, Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation, 1997. 96(10): p. 3549-54.
26.Hillingso, J.G., I.P. Jensen, and L. Tom-Petersen, Parvovirus B19 and acute hepatitis in adults. Lancet, 1998. 351(9107): p. 955-6.
27.Wakamatsu, C., F. Takakura, E. Kojima, Y. Kiriyama, N. Goto, K. Matsumoto, M. Oyama, H. Sato, K. Okochi, and Y. Maeda, Screening of blood donors for human parvovirus B19 and characterization of the results. Vox Sang, 1999. 76(1): p. 14-21.
28.Mori, J., A.M. Field, J.P. Clewley, and B.J. Cohen, Dot blot hybridization assay of B19 virus DNA in clinical specimens. J Clin Microbiol, 1989. 27(3): p. 459-64.
29.Anderson, L.J., C. Tsou, R.A. Parker, T.L. Chorba, H. Wulff, P. Tattersall, and P.P. Mortimer, Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol, 1986. 24(4): p. 522-6.
30.Erdman, D.D., M.J. Usher, C. Tsou, E.O. Caul, G.W. Gary, S. Kajigaya, N.S. Young, and L.J. Anderson, Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol, 1991. 35(2): p. 110-5.
31.Cassinotti, P. and G. Siegl, Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis, 2000. 19(11): p. 886-7.
32.Saal, J.G., M. Steidle, H. Einsele, C.A. Muller, P. Fritz, and J. Zacher, Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int, 1992. 12(4): p. 147-51.
33.Cassinotti, P., G. Burtonboy, M. Fopp, and G. Siegl, Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol, 1997. 53(3): p. 229-32.
34.Patou, G., D. Pillay, S. Myint, and J. Pattison, Characterization of a nested polymerase chain reaction assay for detection of parvovirus B19. J Clin Microbiol, 1993. 31(3): p. 540-6.
35.Harris, J.W., Parvovirus B19 for the hematologist. Am J Hematol, 1992. 39(2): p. 119-30.
36.Schild, R.L., R. Bald, H. Plath, A.M. Eis-Hubinger, G. Enders, and M. Hansmann, Intrauterine management of fetal parvovirus B19 infection. Ultrasound Obstet Gynecol, 1999. 13(3): p. 161-6.
37.Bansal, G.P., J.A. Hatfield, F.E. Dunn, A.A. Kramer, F. Brady, C.H. Riggin, M.S. Collett, K. Yoshimoto, S. Kajigaya, and N.S. Young, Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis, 1993. 167(5): p. 1034-44.
38.Cope, A.P., A. Jones, M. Brozovic, M.S. Shafi, and R.N. Maini, Possible induction of systemic lupus erythematosus by human parvovirus. Ann Rheum Dis, 1992. 51(6): p. 803-4.
39.Loizou, S., J.K. Cazabon, M.J. Walport, D. Tait, and A.K. So, Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum, 1997. 40(1): p. 103-8.
40.Naides, S.J., L.L. Scharosch, F. Foto, and E.J. Howard, Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum, 1990. 33(9): p. 1297-309.
41.Kakurina, N., A. Kadisa, A. Lejnieks, H. Mikazane, S. Kozireva, and M. Murovska, Use of exploratory factor analysis to ascertain the correlation between the activities of rheumatoid arthritis and infection by human parvovirus B19. Medicina (Kaunas), 2015. 51(1): p. 18-24.
42.Ferri, C., K. Zakrzewska, G. Longombardo, D. Giuggioli, F.A. Storino, G. Pasero, and A. Azzi, Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol, 1999. 17(6): p. 718-20.
43.Cioc, A.M., D.D. Sedmak, G.J. Nuovo, M.R. Dawood, G. Smart, and C.M. Magro, Parvovirus B19 associated adult Henoch Schonlein purpura. J Cutan Pathol, 2002. 29(10): p. 602-7.
44.Viguier, M., L. Guillevin, and L. Laroche, Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med, 2001. 344(19): p. 1481-2.
45.Baskan, E.B., E. Yilmaz, H. Saricaoglu, G. Alkan, I. Ercan, R. Mistik, S.B. Adim, G. Goral, K. Dilek, and S. Tunali, Detection of parvovirus B19 DNA in the lesional skin of patients with Behcet''s disease. Clin Exp Dermatol, 2007. 32(2): p. 186-90.
46.Vejlgaard, T.B. and O.B. Nielsen, [Subacute thyroiditis in Parvovirus B19 infection]. Ugeskr Laeger, 1994. 156(41): p. 6039-40.
47.Kerr, J.R., The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease. J Clin Pathol, 2016. 69(4): p. 279-91.
48.Kawase, M., M. Momoeda, N.S. Young, and S. Kajigaya, Most of the VP1 unique region of B19 parvovirus is on the capsid surface. Virology, 1995. 211(2): p. 359-66.
49.Kurtzman, G.J., B.J. Cohen, A.M. Field, R. Oseas, R.M. Blaese, and N.S. Young, Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest, 1989. 84(4): p. 1114-23.
50.Kurtzman, G., N. Frickhofen, J. Kimball, D.W. Jenkins, A.W. Nienhuis, and N.S. Young, Pure red-cell aplasia of 10 years'' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med, 1989. 321(8): p. 519-23.
51.Chandramouli, S., A. Medina-Selby, D. Coit, M. Schaefer, T. Spencer, L.A. Brito, P. Zhang, G. Otten, C.W. Mandl, P.W. Mason, P.R. Dormitzer, and E.C. Settembre, Generation of a parvovirus B19 vaccine candidate. Vaccine, 2013. 31(37): p. 3872-8.
52.Ros, C., M. Gerber, and C. Kempf, Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol, 2006. 80(24): p. 12017-24.
53.Rosenfeld, S.J., N.S. Young, D. Alling, J. Ayub, and C. Saxinger, Subunit interaction in B19 parvovirus empty capsids. Arch Virol, 1994. 136(1-2): p. 9-18.
54.Zuffi, E., E. Manaresi, G. Gallinella, G.A. Gentilomi, S. Venturoli, M. Zerbini, and M. Musiani, Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol, 2001. 14(2): p. 151-8.
55.Kerr, J.R., P.V. Coyle, R.J. DeLeys, and C.C. Patterson, Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection. J Med Virol, 1996. 48(1): p. 68-75.
56.Lindner, J., S. Barabas, K. Saar, D. Altmann, A. Pfister, M. Fleck, L. Deml, and S. Modrow, CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection. J Vet Med B Infect Dis Vet Public Health, 2005. 52(7-8): p. 356-61.
57.Kumar, A., M.F. Perdomo, A. Kantele, L. Hedman, K. Hedman, and R. Franssila, Granzyme B mediated function of Parvovirus B19-specific CD4(+) T cells. Clin Transl Immunology, 2015. 4(7): p. e39.
58.Yoshimoto, K., S. Rosenfeld, N. Frickhofen, D. Kennedy, R. Hills, S. Kajigaya, and N.S. Young, A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune response. Journal of Virology, 1991. 65(12): p. 7056-7060.
59.Saikawa, T., S. Anderson, M. Momoeda, S. Kajigaya, and N.S. Young, Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. Journal of Virology, 1993. 67(6): p. 3004-3009.
60.Sato, H., J. Hirata, N. Kuroda, H. Shiraki, Y. Maeda, and K. Okochi, Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies. Journal of Virology, 1991. 65(10): p. 5485-5490.
61.Brown, C.S., T. Jensen, R.H. Meloen, W. Puijk, K. Sugamura, H. Sato, and W.J. Spaan, Localization of an immunodominant domain on baculovirus-produced parvovirus B19 capsids: correlation to a major surface region on the native virus particle. J Virol, 1992. 66(12): p. 6989-96.
62.Anderson, S., M. Momoeda, M. Kawase, S. Kajigaya, and N.S. Young, Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. Virology, 1995. 206(1): p. 626-32.
63.Leisi, R., N. Ruprecht, C. Kempf, and C. Ros, Parvovirus B19 uptake is a highly selective process controlled by VP1u, a novel determinant of viral tropism. J Virol, 2013. 87(24): p. 13161-7.
64.Leisi, R., C. Di Tommaso, C. Kempf, and C. Ros, The Receptor-Binding Domain in the VP1u Region of Parvovirus B19. Viruses, 2016. 8(3).
65.Lupescu, A., C.T. Bock, P.A. Lang, S. Aberle, H. Kaiser, R. Kandolf, and F. Lang, Phospholipase A2 activity-dependent stimulation of Ca2+ entry by human parvovirus B19 capsid protein VP1. J Virol, 2006. 80(22): p. 11370-80.
66.Filippone, C., N. Zhi, S. Wong, J. Lu, S. Kajigaya, G. Gallinella, L. Kakkola, M. Soderlund-Venermo, N.S. Young, and K.E. Brown, VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology, 2008. 374(2): p. 444-52.
67.Canaan, S., Z. Zadori, F. Ghomashchi, J. Bollinger, M. Sadilek, M.E. Moreau, P. Tijssen, and M.H. Gelb, Interfacial enzymology of parvovirus phospholipases A2. J Biol Chem, 2004. 279(15): p. 14502-8.
68.Deng, X., Y. Dong, Q. Yi, Y. Huang, D. Zhao, Y. Yang, P. Tijssen, J. Qiu, K. Liu, and Y. Li, The determinants for the enzyme activity of human parvovirus B19 phospholipase A2 (PLA2) and its influence on cultured cells. PLoS One, 2013. 8(4): p. e61440.
69.Polcz, M.E., L.A. Adamson, X. Lu, M.N. Chang, L.J. Fowler, and J.A. Hobbs, Increased IL-6 detection in adult and pediatric lymphoid tissue harboring parvovirus B19. J Clin Virol, 2013. 57(3): p. 233-8.
70.Tsai, C.C., B.S. Tzang, S.Y. Chiang, G.J. Hsu, and T.C. Hsu, Increased expression of Matrix Metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. J Biomed Sci, 2009. 16: p. 14.
71.Takahashi, Y., C. Murai, S. Shibata, Y. Munakata, T. Ishii, K. Ishii, T. Saitoh, T. Sawai, K. Sugamura, and T. Sasaki, Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A, 1998. 95(14): p. 8227-32.
72.Tzang, B.S., C.C. Chiu, C.C. Tsai, Y.J. Lee, I.J. Lu, J.Y. Shi, and T.C. Hsu, Effects of human parvovirus B19 VP1 unique region protein on macrophage responses. J Biomed Sci, 2009. 16: p. 13.
73.Nie, X., G. Zhang, D. Xu, X. Sun, Z. Li, X. Li, X. Zhang, F. He, and Y. Li, The VP1-unique region of parvovirus B19 induces myocardial injury in mice. Scand J Infect Dis, 2010. 42(2): p. 121-8.
74.Tzang, B.S., T.M. Lin, C.C. Tsai, J.D. Hsu, L.C. Yang, and T.C. Hsu, Increased cardiac injury in NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. Mol Immunol, 2011. 48(12-13): p. 1518-24.
75.Hsu, T.C., C.C. Chiu, S.C. Chang, H.C. Chan, Y.F. Shi, T.Y. Chen, and B.S. Tzang, Human parvovirus B19 VP1u Protein as inflammatory mediators induces liver injury in naive mice. Virulence, 2016. 7(2): p. 110-8.
76.Hughes, G.R., N.N. Harris, and A.E. Gharavi, The anticardiolipin syndrome. J Rheumatol, 1986. 13(3): p. 486-9.
77.Cervera, R., S. Bucciarelli, M.A. Plasin, J.A. Gomez-Puerta, J. Plaza, G. Pons-Estel, Y. Shoenfeld, M. Ingelmo, and G. Espinos, Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun, 2009. 32(3-4): p. 240-5.
78.Tenti, S., S. Cheleschi, G.M. Guidelli, M. Galeazzi, and A. Fioravanti, Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. Autoimmun Rev, 2016. 15(3): p. 226-35.
79.Meroni, P.L., M.O. Borghi, E. Raschi, and F. Tedesco, Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol, 2011. 7(6): p. 330-9.
80.Petri, M., Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun, 2000. 15(2): p. 145-51.
81.McNeil, H.P., R.J. Simpson, C.N. Chesterman, and S.A. Krilis, Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A, 1990. 87(11): p. 4120-4.
82.Gharavi, A.E., S.S. Pierangeli, and E.N. Harris, Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies. Immunobiology, 2003. 207(1): p. 37-42.
83.Gharavi, A.E., L.R. Sammaritano, J. Wen, and K.B. Elkon, Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest, 1992. 90(3): p. 1105-9.
84.Gharavi, A.E., L.R. Sammaritano, J.L. Bovastro, Jr., and W.A. Wilson, Specificities and characteristics of beta 2 glycoprotein I-induced antiphospholipid antibodies. J Lab Clin Med, 1995. 125(6): p. 775-8.
85.Pierangeli, S.S., P.P. Chen, E. Raschi, S. Scurati, C. Grossi, M.O. Borghi, I. Palomo, E.N. Harris, and P.L. Meroni, Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost, 2008. 34(3): p. 236-50.
86.de Laat, B., K. Mertens, and P.G. de Groot, Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol, 2008. 4(4): p. 192-9.
87.Erkan, D., C.L. Aguiar, D. Andrade, H. Cohen, M.J. Cuadrado, A. Danowski, R.A. Levy, T.L. Ortel, A. Rahman, J.E. Salmon, M.G. Tektonidou, R. Willis, and M.D. Lockshin, 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev, 2014. 13(6): p. 685-96.
88.Sasaki, T., Y. Takahashi, K. Yoshinaga, K. Sugamura, and H. Shiraishi, An association between human parvovirus B-19 infection and autoantibody production. J Rheumatol, 1989. 16(5): p. 708-9.
89.Kerr, J.R. and N. Boyd, Autoantibodies following parvovirus B19 infection. J Infect, 1996. 32(1): p. 41-7.
90.Hansen, K.E., J. Arnason, and A.J. Bridges, Autoantibodies and common viral illnesses. Semin Arthritis Rheum, 1998. 27(5): p. 263-71.
91.Von Landenberg, P., H.W. Lehmann, A. Knoll, S. Dorsch, and S. Modrow, Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum, 2003. 48(7): p. 1939-47.
92.Tzang, B.S., Y.J. Lee, T.P. Yang, G.J. Tsay, J.Y. Shi, C.C. Tsai, and T.C. Hsu, Induction of antiphospholipid antibodies and antiphospholipid syndrome-like autoimmunity in naive mice with antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta, 2007. 382(1-2): p. 31-6.
93.Tzang, B.S., C.C. Tsai, C.C. Chiu, J.Y. Shi, and T.C. Hsu, Up-regulation of adhesion molecule expression and induction of TNF-alpha on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta, 2008. 395(1-2): p. 77-83.
94.Chen, D.Y., B.S. Tzang, Y.M. Chen, J.L. Lan, C.C. Tsai, and T.C. Hsu, The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clin Chim Acta, 2010. 411(15-16): p. 1084-9.
95.Grass, D.S., R.H. Felkner, M.Y. Chiang, R.E. Wallace, T.J. Nevalainen, C.F. Bennett, and M.E. Swanson, Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J Clin Invest, 1996. 97(10): p. 2233-41.
96.Gilroy, D.W., J. Newson, P. Sawmynaden, D.A. Willoughby, and J.D. Croxtall, A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J, 2004. 18(3): p. 489-98.
97.Thommesen, L., W. Sjursen, K. Gasvik, W. Hanssen, O.L. Brekke, L. Skattebol, A.K. Holmeide, T. Espevik, B. Johansen, and A. Laegreid, Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-kappa B and expression of ICAM-1. J Immunol, 1998. 161(7): p. 3421-30.
98.Zadori, Z., J. Szelei, M.C. Lacoste, Y. Li, S. Gariepy, P. Raymond, M. Allaire, I.R. Nabi, and P. Tijssen, A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell, 2001. 1(2): p. 291-302.
99.Underhill, D.M., M. Bassetti, A. Rudensky, and A. Aderem, Dynamic interactions of macrophages with T cells during antigen presentation. J Exp Med, 1999. 190(12): p. 1909-14.
100.Franssila, R., K. Hokynar, and K. Hedman, T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19. J Infect Dis, 2001. 183(5): p. 805-9.
101.Franssila, R., J. Auramo, S. Modrow, M. Mobs, C. Oker-Blom, P. Kapyla, M. Soderlund-Venermo, and K. Hedman, T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity. Clin Exp Immunol, 2005. 142(1): p. 53-61.
102.Corcoran, A., S. Doyle, D. Waldron, A. Nicholson, and B.P. Mahon, Impaired gamma interferon responses against parvovirus B19 by recently infected children. J Virol, 2000. 74(21): p. 9903-10.
103.Tolfvenstam, T., A. Oxenius, D.A. Price, B.L. Shacklett, H.M. Spiegel, K. Hedman, O. Norbeck, M. Levi, K. Olsen, M. Kantzanou, D.F. Nixon, K. Broliden, and P. Klenerman, Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19. J Virol, 2001. 75(1): p. 540-3.
104.Norbeck, O., A. Isa, C. Pohlmann, K. Broliden, V. Kasprowicz, P. Bowness, P. Klenerman, and T. Tolfvenstam, Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol, 2005. 79(18): p. 12117-21.
105.Isa, A., V. Kasprowicz, O. Norbeck, A. Loughry, K. Jeffery, K. Broliden, P. Klenerman, T. Tolfvenstam, and P. Bowness, Prolonged activation of virus-specific CD8+T cells after acute B19 infection. PLoS Med, 2005. 2(12): p. e343.
106.McGuirk, P. and K.H. Mills, Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol, 2002. 23(9): p. 450-5.
107.Lochner, M., Z. Wang, and T. Sparwasser, The Special Relationship in the Development and Function of T Helper 17 and Regulatory T Cells. Prog Mol Biol Transl Sci, 2015. 136: p. 99-129.
108.Musiani, M., E. Manaresi, G. Gallinella, S. Venturoli, E. Zuffi, and M. Zerbini, Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J Med Virol, 2000. 60(3): p. 347-52.
109.Moffatt, S., N. Tanaka, K. Tada, M. Nose, M. Nakamura, O. Muraoka, T. Hirano, and K. Sugamura, A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol, 1996. 70(12): p. 8485-91.
110.Thammasri, K., S. Rauhamaki, L. Wang, A. Filippou, V. Kivovich, V. Marjomaki, S.J. Naides, and L. Gilbert, Human parvovirus B19 induced apoptotic bodies contain altered self-antigens that are phagocytosed by antigen presenting cells. PLoS One, 2013. 8(6): p. e67179.
111.Lunardi, C., M. Tiso, L. Borgato, L. Nanni, R. Millo, G. De Sandre, A.B. Severi, and A. Puccetti, Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol, 1998. 28(3): p. 936-48.
112.Lu, J., N. Zhi, S. Wong, and K.E. Brown, Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis, 2006. 193(4): p. 582-90.
113.Ballou, W.R., J.L. Reed, W. Noble, N.S. Young, and S. Koenig, Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis, 2003. 187(4): p. 675-8.
114.Bernstein, D.I., H.M. El Sahly, W.A. Keitel, M. Wolff, G. Simone, C. Segawa, S. Wong, D. Shelly, N.S. Young, and W. Dempsey, Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine, 2011. 29(43): p. 7357-63.
115.Rodriguez De Turco, E.B., F.R. Jackson, M.A. DeCoster, M. Kolko, and N.G. Bazan, Glutamate signalling and secretory phospholipase A2 modulate the release of arachidonic acid from neuronal membranes. J Neurosci Res, 2002. 68(5): p. 558-67.
116.Fasano, C. and D. Kanduc, Selfness-nonselfness in designing an anti-B19 erythrovirus vaccine. Self Nonself, 2011. 2(2): p. 114-119.
117.Gigler, A., S. Dorsch, A. Hemauer, C. Williams, S. Kim, N.S. Young, S. Zolla-Pazner, H. Wolf, M.K. Gorny, and S. Modrow, Generation of Neutralizing Human Monoclonal Antibodies against Parvovirus B19 Proteins. J Virol, 1999. 73(3): p. 1974-9.
118.Manaresi, E., G. Gallinella, M. Zerbini, S. Venturoli, G. Gentilomi, and M. Musiani, IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay. J Med Virol, 1999. 57(2): p. 174-8.
119.Saikawa, T., S. Anderson, M. Momoeda, S. Kajigaya, and N.S. Young, Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol, 1993. 67(6): p. 3004-9.
120.Corcoran, A., B.P. Mahon, and S. Doyle, B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1. J Infect Dis, 2004. 189(10): p. 1873-80.